{"id":"adrafinil","rwe":[{"pmid":"40241641","year":"2025","title":"Transition-metal free chemoselective C-H hydroxylation of bisarylmethanes enabled by a phosphite as a sacrificial reductant.","finding":"","journal":"Organic & biomolecular chemistry","studyType":"Clinical Study"},{"pmid":"39999562","year":"2025","title":"In silico tuning of binding selectivity for new SARS-CoV-2 main protease inhibitors.","finding":"","journal":"Computer methods and programs in biomedicine","studyType":"Clinical Study"},{"pmid":"39466147","year":"2025","title":"Development and Validation of an Analytical Method to Identify and Quantitate Novel Modafinil Analogs in Products Marketed as Dietary Supplements.","finding":"","journal":"Journal of dietary supplements","studyType":"Clinical Study"},{"pmid":"33457050","year":"2020","title":"Identification of adrafinil and its main metabolite modafinil in human hair. Self-administration study and interpretation of an authentic case.","finding":"","journal":"Forensic sciences research","studyType":"Clinical Study"},{"pmid":"32447354","year":"2020","title":"The role of eugeroics in the treatment of affective disorders.","finding":"","journal":"Psychiatria polska","studyType":"Clinical Study"}],"tags":[{"label":"adrafinil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N06BX17","category":"atc"},{"label":"Active","category":"status"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic alpha-Agonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"olmifon","offLabel":[],"synonyms":["adrafinil","olmifon","benzhydrylsulfinylacetohydroxamic acid","adrafinyl","CRL-40028"],"timeline":[],"brandName":"Olmifon","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"adrafinil","explanation":"Think of neurotransmitters like messengers that help different parts of the brain talk to each other. Olmifon helps increase the amount of these messengers, which can help improve alertness, energy, and focus. This can be helpful for people who need to stay awake and alert during long periods of time, such as shift workers or people with sleep disorders.","oneSentence":"Olmifon works by increasing the production of neurotransmitters in the brain, such as dopamine and norepinephrine.","technicalDetail":"Olmifon is a prodrug that is metabolized to its active form, modafinil, which acts as a selective and reversible inhibitor of the enzyme responsible for the breakdown of dopamine, norepinephrine, and other neurotransmitters, leading to increased levels of these neurotransmitters in the synaptic cleft."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Adrafinil","title":"Adrafinil","extract":"Adrafinil, sold under the brand name Olmifon, is a wakefulness-promoting medication that was formerly used in France to improve alertness, attention, wakefulness, and mood, particularly in the elderly. It was also used off-label by individuals who wished to avoid fatigue, such as night workers or others who needed to stay awake and alert for long periods of time. Additionally, the medication has been used non-medically as a novel vigilance-promoting agent.","wiki_history":"==History==\nAdrafinil was discovered in 1974 by two chemists working for the French pharmaceutical company Laboratoires Lafon who were screening compounds in search of analgesics. Pharmacological studies of adrafinil instead revealed psychostimulant-like effects such as hyperactivity and wakefulness in animals.\n\nIn 1976, two years after the discovery of adrafinil, its active metabolite  modafinil was discovered. As of September 2011, Cephalon has discontinued Olmifon, its adrafinil product, while modafinil continues to be marketed.","wiki_society_and_culture":"==Society and culture==\n\n===Names===\nAdrafinil is the generic name of the drug and its  and .\n\n==== Additive in United States dietary supplements ====\nAdrafinil is sometimes included as an ingredient in misbranded or adulterated dietary supplements. One company had attempted to get a New Dietary Ingredient pre-market notification approved for adrafinil in 2017, but the Food and Drug Administration rejected it:\n\n\n\nA position that adrafinil is an unapproved drug was indicated in a warning letter\n\nAdrafinil containing products, purporting to be dietary supplements, are not allowed for use by military service members. This is because the Department of Defense considers adrafinil an unapproved drug.\n\n====New Zealand====\nIn 2005 a Medical Classification Committee in New Zealand recommended to MEDSAFE NZ that adrafinil be classified as a prescription medicine due to risks of it being used as a party drug.  At that time adrafinil was not scheduled in New Zealand."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/95","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ADRAFINIL","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Adrafinil","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:29:11.234226","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:15:56.443561+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"adrafinil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005222","UNII":"BI81Z4542G","CHEBI":"CHEBI:135200","INN_ID":"5110","RXNORM":"45938","UMLSCUI":"C0101700","ChEMBL_ID":"CHEMBL93077","KEGG_DRUG":"D07348","DRUGBANK_ID":"DB08925","PDB_CHEM_ID":"RNW","PUBCHEM_CID":"3033226","MESH_SUPPLEMENTAL_RECORD_UI":"C022116"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":36,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N06BX17","allCodes":["N06BX17"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 May 14","pmid":"40241641","title":"Transition-metal free chemoselective C-H hydroxylation of bisarylmethanes enabled by a phosphite as a sacrificial reductant.","journal":"Organic & biomolecular chemistry"},{"date":"2025 Apr","pmid":"39999562","title":"In silico tuning of binding selectivity for new SARS-CoV-2 main protease inhibitors.","journal":"Computer methods and programs in biomedicine"},{"date":"2025","pmid":"39466147","title":"Development and Validation of an Analytical Method to Identify and Quantitate Novel Modafinil Analogs in Products Marketed as Dietary Supplements.","journal":"Journal of dietary supplements"},{"date":"2020 Jan 29","pmid":"33457050","title":"Identification of adrafinil and its main metabolite modafinil in human hair. Self-administration study and interpretation of an authentic case.","journal":"Forensic sciences research"},{"date":"2020 Feb 29","pmid":"32447354","title":"The role of eugeroics in the treatment of affective disorders.","journal":"Psychiatria polska"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olmifon, also known as Adrafinil, is a small molecule drug of the adrafinil class. It was originally developed by Louis Lafon, a French chemist, and is currently owned by a private company. The exact target of Olmifon is unknown, but it is believed to work by increasing the production of neurotransmitters such as dopamine and norepinephrine in the brain. Olmifon is not FDA-approved for any indications and is considered an off-patent, generic medication. Key safety considerations include potential liver toxicity and interactions with other medications.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:15:56.443561+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}